BPMC - FDA OKs Blueprint Medicines and Roche's Gavreto for type of medullary thyroid cancer

Blueprint Medicines ([[BPMC]] -2.5%) and collaboration partner Roche ([[RHHBY]] +2.1%) announce the FDA nod for Gavreto (pralsetinib) for the treatment of advanced/metastatic RET fusion-positive medullary thyroid cancer in patients at least 12 years old who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).The agency approved the kinase inhibitor in September for adults with RET fusion-positive non-small cell lung cancer.

For further details see:

FDA OKs Blueprint Medicines and Roche's Gavreto for type of medullary thyroid cancer